Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPV

Prior treatment

• Previous vaccination or planned receipt of any vaccine against diphtheria, tetanus, pertussis, hepatitis B (except birth dose), poliomyelitis (except OPV birth dose) or Haemophilus Influenzae type b infection apart from trial vaccines during the study period.
• Administration of any vaccine (except OPV during government immunization campaign) in the 4 weeks preceding the first trial vaccination.
• Infants with known or suspected impairment of the immune function, or those receiving immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy or received immunosuppressive therapy prior to study entry
• Planned surgery during the study.

Other illness

• History of diphtheria/ tetanus/ pertussis/ hepatitis B/ Haemophilus Influenzae type b/ poliomyelitis infection(s).
• Acute illness of moderate to severe intensity according to the clinical judgment of the investigator .
• History of major congenital defects or illness that require medical therapy, as determined by medical history or clinical assessment.
• History of any clinically significant chronic disease that in the opinion of the Investigator, might interfere with the evaluation of the study objectives.
• History of anaphylaxis, or any serious vaccine reaction, or hypersensitivity/allergy to any vaccine or components of study vaccine.
• Presence of evolving or changing neurological disorder or infant with a history of seizures and/or encephalopathy.
• Known thrombocytopenia or a bleeding disorder.
• Known personal or maternal history of HIV, Hepatitis B or Hepatitis C seropositivity.

Other

• Presence of fever ≥ 38°C/ 100.4°F.
• Receipt of antibiotics in the past 3 days
• Receipt of blood or blood-derived products or immunoglobulins or planned administration during the trial which might interfere with the assessment of the immune response.
• Participation in another clinical trial 4 weeks preceding the trial enrolment or planned participation during the present trial period in another clinical trial.
• Infants whose families are planning to leave the area of the study site before the end of the study period.

• Male or female infants aged 6-8 weeks at the time of first vaccination.
• Infants with good health, as determined by the medical history, physical examination and clinical judgment of the Investigator.
• Informed consent form signed by at least one parent.
• Infants born at full term pregnancy (≥ 37 weeks).
• Infants with weight-for-length z-score ≥ -2 standard deviation (SD) at the time of enrolment.
• Willingness of subjects' parent to comply with the requirements of the protocol.